TL;DR: Cannabis earnings require sector-specific interpretation. Look beyond revenue to adjusted EBITDA, free cash flow, and the 280E tax drag. Guidance and debt load are equally important. Track quarterly results at weedstock.com/tracker/.
Why Cannabis Earnings Are Different
Every quarter, cannabis companies release financial results that look superficially like any other public company’s earnings report. There’s revenue, gross profit, operating expenses, and net income. But underneath those standard line items lies a set of dynamics that are unique to cannabis — and misunderstanding them leads to poor investment decisions.
The two biggest distortions: IRC Section 280E taxation and non-cash stock compensation charges. Together, they can make a fundamentally profitable cannabis business look catastrophically unprofitable on a GAAP basis. The key is knowing what to look for and what to look past.
Revenue: The Top Line
Cannabis companies typically report both gross revenue (total before discounts and returns) and net revenue (after deductions). Always use net revenue for comparisons. Look for these additional revenue metrics:
- Revenue by segment: Retail, wholesale, and sometimes medical vs. adult-use. Retail margins are typically higher than wholesale.
- Same-store sales (SSS) growth: Like retail sector analysis, SSS strips out new store openings to show organic growth at existing locations. A company adding stores but declining on SSS is a warning sign.
- Revenue per dispensary: Divide total retail revenue by number of open dispensaries. This shows operational efficiency and is useful for MSO comparisons.
Gross Margin: The Efficiency Signal
Gross margin (gross profit ÷ net revenue) measures how efficiently a company converts sales into profit after direct costs. Industry benchmarks for MSOs:
- 50%+ gross margin: Strong. Indicates good cultivation efficiency or premium product positioning.
- 40–50%: Acceptable, especially for newer or fast-growing operators.
- Below 40%: Concerning unless there’s a clear operational explanation.
The 280E Tax Problem — And Adjusted EBITDA
Section 280E of the Internal Revenue Code prohibits businesses “trafficking in controlled substances” from deducting ordinary business expenses on their federal taxes. For cannabis companies, this means they can only deduct the cost of goods sold (COGS) — not rent, salaries, marketing, G&A, or any other operating expense.
The practical effect: a cannabis company with $200M revenue, $100M COGS, and $80M in operating expenses has $20M in GAAP operating income. But under 280E, taxable income is computed on the $100M gross profit — resulting in a federal tax bill that can exceed GAAP operating income entirely. Companies frequently show net losses on GAAP while being operationally profitable on a pre-tax basis.
This is why cannabis analysts focus almost exclusively on Adjusted EBITDA: earnings before interest, taxes, depreciation, and amortization, further adjusted to remove stock-based compensation and one-time charges. Adjusted EBITDA represents the cash-generating capacity of the core business and strips out the 280E distortion.
Key adjusted EBITDA metrics:
- Positive adjusted EBITDA: The baseline for operational health.
- Adjusted EBITDA margin (adj. EBITDA ÷ revenue): Target 15–25% for mature operators.
- Year-over-year improvement: Trend matters as much as absolute level.
Free Cash Flow: The Real Test
Adjusted EBITDA is a useful proxy, but free cash flow (FCF) is the ultimate test of financial health. FCF = operating cash flow minus capital expenditures. A company with strong adjusted EBITDA but negative FCF is either investing heavily in growth (acceptable if well-managed) or burning cash through working capital needs or high interest payments (a warning sign).
Free cash flow positive cannabis companies are rare and command premium valuations because they can self-fund operations without diluting shareholders. When a cannabis MSO achieves consistent positive FCF, it represents a significant operational milestone worth noting in your analysis.
Debt and Balance Sheet Health
Cannabis companies have historically relied on expensive debt financing due to limited banking access. Key things to check:
- Total debt and maturity schedule: When does debt come due? Refinancing risk in a tight capital environment is real.
- Interest rates: Cannabis debt often carries 10–14% interest rates — a massive drag on earnings.
- Net debt leverage: Compare net debt (debt minus cash) to adjusted EBITDA. Net debt / EBITDA above 4–5x is concerning for a cannabis company.
Guidance: Forward-Looking Signals
Cannabis companies often provide revenue and adjusted EBITDA guidance for the upcoming quarter or full year. What matters most:
- Did the company beat or miss prior guidance? Consistently missing is a management quality signal.
- What are the underlying assumptions? Market openings, pricing assumptions, cost savings — test whether they’re realistic.
- Raising or lowering guidance? Mid-year guidance cuts are a red flag; raises are a bullish signal.
The Complete Cannabis Earnings Checklist
- Net revenue growth YoY and QoQ
- Gross margin trend
- Adjusted EBITDA and margin
- 280E tax accrual and effective tax rate
- Free cash flow (positive or negative)
- Debt load and maturity profile
- Same-store sales growth at existing locations
- Guidance vs. prior guidance
- Fully diluted share count changes
Master these nine data points and you’ll have a clearer picture of any cannabis company’s earnings than most retail investors. For earnings calendars and real-time price reactions when results drop, our Cannabis Stock Tracker keeps you current on all major cannabis earnings events.